How to appeal a Highmark lupus & rheumatology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for lupus & rheumatology

Cited policy: BCBS medical policy: Rituximab for Off-Label Indications in SLE / Lupus Nephritis

Refractory SLE or LN despite ≥6 mo of MMF or IV CYC. Severe hematologic SLE (refractory ITP <30k or AIHA Hgb <8) per ACR / EULAR. Refractory NPSLE. Pregnancy or planned pregnancy where MMF/CYC/MTX contraindicated (ACR 2020 Reproductive Guideline). 1 g IV x 2 doses (days 0 + 14) or 375 mg/m² weekly x 4 doses. Coverage as Category 2A NCCN-equivalent off-label.

How Highmark denies lupus & rheumatology — and how to counter it

Where Highmark pushes back: 1) Off-label, not FDA-approved for SLE; 2) LUNAR + EXPLORER trials failed primary endpoints; 3) Less expensive alternatives available.

Counter-arguments that hold up: EULAR 2023 SLE Recs explicitly include rituximab for refractory hematologic SLE (ITP/AIHA), refractory NPSLE, and pregnancy when teratogens (MMF/CYC/MTX) contraindicated. ACR 2020 Reproductive Health Guideline recommends rituximab pre-pregnancy. KDIGO 2024 LN guideline supports rituximab as alternative when standard therapy contraindicated/failed. While LUNAR ART 2012 missed primary endpoint, secondary outcomes showed C3/C4 normalization + anti-dsDNA reduction; observational registries (>400 patients) report 67-77% renal response in refractory LN. REGENCY Phase 3 obinutuzumab positive 2024 confirms anti-CD20 class effect in LN. Compendia support: Micromedex 2A, AHFS 2A — qualifies for off-label coverage under state external-review statutes.

What Highmark typically denies for lupus & rheumatology

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For lupus & rheumatology, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the lupus & rheumatology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Benlysta
• Saphnelo
• Lupkynis
• Hydroxychloroquine
• Mycophenolate (MMF)
• Cyclophosphamide IV

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.